Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cancervax Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is assigned to 1 distinct examiner, ALDARONDO, DASIA ALI, who is the busiest examiner for the portfolio. The involvement of 1 distinct art unit suggests that the company's current legal activity is highly concentrated within a specific technical niche.
ALDARONDO, DASIA ALI is responsible for 1 busiest examiner pending action, which represents the total number of 1 pending office action currently active. This alignment indicates that the company's prosecution strategy is centralized under a single reviewer. The 1 distinct art unit involved further reinforces the focused nature of the company's current efforts in Biotechnology & Pharmaceuticals.
For a practitioner, this level of concentration simplifies the management of the portfolio, as there is only 1 distinct examiner to interact with. The success of the current applications depends entirely on the 1 busiest examiner pending action. There is no need to coordinate across multiple art units, allowing for a very targeted approach to the pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698262 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | ALDARONDO, DASIA ALI | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698262 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | ALDARONDO, DASIA ALI | 1647 | §103§112 | Non-Final OA | — | Pending | Apr 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCancervax Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dasia Ali Aldarondo has the most, with 1 of Cancervax Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
